Bone metastases and non-small cell lung cancer: From bisphosfonates to targeted therapy

A. Rossi, C. Gridelli, S. Ricciardi, F. De Marinis

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

About 30-40% of patients affected by non-small cell lung cancer (NSCLC) develop, during the course of their disease, bone metastases. The prognosis of these patients is poor with a median survival of less than 1 year. The therapeutic approach includes: palliative radiotherapy, and systemic therapy. In clinical practice, zoledronate is the most commonly used bisphosphonate to prevent, reduce the incidence and delay the onset of skeletal-related events in patients with metastatic NSCLC. However, an Italian Association of Thoracic Oncology (AIOT) survey, conducted to evaluate how bisphosphonates were used in clinical practice for the treatment of lung cancer bone metastases in Italy, showed that the bisphosphonates treatment is still not routine and varies in duration. Denosumab is a fully human monoclonal antibody directed against the receptor activator of nuclear factor kappa-B (RANK)-Ligand inhibiting the maturation of pre-osteoclasts into osteoclasts and is the first example of targeted therapy for bone metastases. An exploratory analysis showed that denosumab was associated with improved overall survival compared with zoledronate in patients with bone metastases from lung cancer. Biochemical markers of bone turnover to predict what patients are at greatest risk of developing skeletal-related events, and to direct treatment of bone metastases with either bisphosphonates or denosumab, are under investigation. This review is focused on the systemic management of bone metastases from NSCLC.

Original languageEnglish
Pages (from-to)5524-5535
Number of pages12
JournalCurrent Medicinal Chemistry
Volume19
Issue number32
DOIs
Publication statusPublished - Nov 2012

Fingerprint

Non-Small Cell Lung Carcinoma
Bone
zoledronic acid
Cells
Diphosphonates
Neoplasm Metastasis
Bone and Bones
Osteoclasts
Lung Neoplasms
Therapeutics
RANK Ligand
Bone Neoplasms
Survival
Bone Remodeling
Bone Diseases
Oncology
Radiotherapy
Italy
Thorax
Biomarkers

Keywords

  • AIOT
  • Biomarkers
  • Bisphosphonates
  • Bone metastasis
  • Denosumab
  • Lung cancer
  • NSCLC
  • Zoledronate

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Bone metastases and non-small cell lung cancer : From bisphosfonates to targeted therapy. / Rossi, A.; Gridelli, C.; Ricciardi, S.; De Marinis, F.

In: Current Medicinal Chemistry, Vol. 19, No. 32, 11.2012, p. 5524-5535.

Research output: Contribution to journalArticle

Rossi, A. ; Gridelli, C. ; Ricciardi, S. ; De Marinis, F. / Bone metastases and non-small cell lung cancer : From bisphosfonates to targeted therapy. In: Current Medicinal Chemistry. 2012 ; Vol. 19, No. 32. pp. 5524-5535.
@article{d2d1d466baae4e918079e7bc6953bbce,
title = "Bone metastases and non-small cell lung cancer: From bisphosfonates to targeted therapy",
abstract = "About 30-40{\%} of patients affected by non-small cell lung cancer (NSCLC) develop, during the course of their disease, bone metastases. The prognosis of these patients is poor with a median survival of less than 1 year. The therapeutic approach includes: palliative radiotherapy, and systemic therapy. In clinical practice, zoledronate is the most commonly used bisphosphonate to prevent, reduce the incidence and delay the onset of skeletal-related events in patients with metastatic NSCLC. However, an Italian Association of Thoracic Oncology (AIOT) survey, conducted to evaluate how bisphosphonates were used in clinical practice for the treatment of lung cancer bone metastases in Italy, showed that the bisphosphonates treatment is still not routine and varies in duration. Denosumab is a fully human monoclonal antibody directed against the receptor activator of nuclear factor kappa-B (RANK)-Ligand inhibiting the maturation of pre-osteoclasts into osteoclasts and is the first example of targeted therapy for bone metastases. An exploratory analysis showed that denosumab was associated with improved overall survival compared with zoledronate in patients with bone metastases from lung cancer. Biochemical markers of bone turnover to predict what patients are at greatest risk of developing skeletal-related events, and to direct treatment of bone metastases with either bisphosphonates or denosumab, are under investigation. This review is focused on the systemic management of bone metastases from NSCLC.",
keywords = "AIOT, Biomarkers, Bisphosphonates, Bone metastasis, Denosumab, Lung cancer, NSCLC, Zoledronate",
author = "A. Rossi and C. Gridelli and S. Ricciardi and {De Marinis}, F.",
year = "2012",
month = "11",
doi = "10.2174/092986712803833209",
language = "English",
volume = "19",
pages = "5524--5535",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "32",

}

TY - JOUR

T1 - Bone metastases and non-small cell lung cancer

T2 - From bisphosfonates to targeted therapy

AU - Rossi, A.

AU - Gridelli, C.

AU - Ricciardi, S.

AU - De Marinis, F.

PY - 2012/11

Y1 - 2012/11

N2 - About 30-40% of patients affected by non-small cell lung cancer (NSCLC) develop, during the course of their disease, bone metastases. The prognosis of these patients is poor with a median survival of less than 1 year. The therapeutic approach includes: palliative radiotherapy, and systemic therapy. In clinical practice, zoledronate is the most commonly used bisphosphonate to prevent, reduce the incidence and delay the onset of skeletal-related events in patients with metastatic NSCLC. However, an Italian Association of Thoracic Oncology (AIOT) survey, conducted to evaluate how bisphosphonates were used in clinical practice for the treatment of lung cancer bone metastases in Italy, showed that the bisphosphonates treatment is still not routine and varies in duration. Denosumab is a fully human monoclonal antibody directed against the receptor activator of nuclear factor kappa-B (RANK)-Ligand inhibiting the maturation of pre-osteoclasts into osteoclasts and is the first example of targeted therapy for bone metastases. An exploratory analysis showed that denosumab was associated with improved overall survival compared with zoledronate in patients with bone metastases from lung cancer. Biochemical markers of bone turnover to predict what patients are at greatest risk of developing skeletal-related events, and to direct treatment of bone metastases with either bisphosphonates or denosumab, are under investigation. This review is focused on the systemic management of bone metastases from NSCLC.

AB - About 30-40% of patients affected by non-small cell lung cancer (NSCLC) develop, during the course of their disease, bone metastases. The prognosis of these patients is poor with a median survival of less than 1 year. The therapeutic approach includes: palliative radiotherapy, and systemic therapy. In clinical practice, zoledronate is the most commonly used bisphosphonate to prevent, reduce the incidence and delay the onset of skeletal-related events in patients with metastatic NSCLC. However, an Italian Association of Thoracic Oncology (AIOT) survey, conducted to evaluate how bisphosphonates were used in clinical practice for the treatment of lung cancer bone metastases in Italy, showed that the bisphosphonates treatment is still not routine and varies in duration. Denosumab is a fully human monoclonal antibody directed against the receptor activator of nuclear factor kappa-B (RANK)-Ligand inhibiting the maturation of pre-osteoclasts into osteoclasts and is the first example of targeted therapy for bone metastases. An exploratory analysis showed that denosumab was associated with improved overall survival compared with zoledronate in patients with bone metastases from lung cancer. Biochemical markers of bone turnover to predict what patients are at greatest risk of developing skeletal-related events, and to direct treatment of bone metastases with either bisphosphonates or denosumab, are under investigation. This review is focused on the systemic management of bone metastases from NSCLC.

KW - AIOT

KW - Biomarkers

KW - Bisphosphonates

KW - Bone metastasis

KW - Denosumab

KW - Lung cancer

KW - NSCLC

KW - Zoledronate

UR - http://www.scopus.com/inward/record.url?scp=84870406259&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870406259&partnerID=8YFLogxK

U2 - 10.2174/092986712803833209

DO - 10.2174/092986712803833209

M3 - Article

C2 - 22963665

AN - SCOPUS:84870406259

VL - 19

SP - 5524

EP - 5535

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 32

ER -